中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2012年
12期
1076-1078
,共3页
景元明%杨飞英%叶民峰%陶锋
景元明%楊飛英%葉民峰%陶鋒
경원명%양비영%협민봉%도봉
胃肿瘤%血管内皮生长因子类%人参皂甙
胃腫瘤%血管內皮生長因子類%人參皂甙
위종류%혈관내피생장인자류%인삼조대
Stomach neoplasms%Vascular endothelial growth factors%Angiogenesis inhibitors%Ginsenoside
目的 探讨人参皂甙Rg3联合XELOX方案对老年胃癌的治疗效果.方法 将确诊为老年晚期胃癌(Ⅳ期)的93例患者随机分为两组:对照组53例(XELOX方案化疗);研究组40例(XELOX方案化疗+人参皂甙Rg3).观察两组患者的客观有效率(RR)、远期生活质量(KPS)评分,并检测2组患者血清血管内皮生长因子(VEGF)水平.结果 研究组、对照组治疗前血清VEGF水平分别为(387.63±159.74)μg/L和(378.56±169.36) ng/L;治疗第8周后检测血清VEGF水平,研究组VEGF水平降至(207.74±115.71)ng/L,对照组VEGF水平降至(246.53±107.63)μg/L.治疗后两组组间相比,血清VEGF水平均有统计学意义(Z＝4.275,P＜0.05).研究组客观有效率为57.5％(23/40),对照组为45.3％(24/53),差异无统计学意义(x2＝1.36,P＞0.05).研究组KPS评分上升率(65.0％)高于对照组(39.6％),(x2 ＝5.87,P＜0.05).研究组和对照组无进展生存期分别为5.38个月和6.92个月(x2＝4.04,P＜0.05).结论 人参皂苷Rg3联合化疗可以降低老年胃癌患者血清VEGF水平,改善患者的一般状况.
目的 探討人參皂甙Rg3聯閤XELOX方案對老年胃癌的治療效果.方法 將確診為老年晚期胃癌(Ⅳ期)的93例患者隨機分為兩組:對照組53例(XELOX方案化療);研究組40例(XELOX方案化療+人參皂甙Rg3).觀察兩組患者的客觀有效率(RR)、遠期生活質量(KPS)評分,併檢測2組患者血清血管內皮生長因子(VEGF)水平.結果 研究組、對照組治療前血清VEGF水平分彆為(387.63±159.74)μg/L和(378.56±169.36) ng/L;治療第8週後檢測血清VEGF水平,研究組VEGF水平降至(207.74±115.71)ng/L,對照組VEGF水平降至(246.53±107.63)μg/L.治療後兩組組間相比,血清VEGF水平均有統計學意義(Z＝4.275,P＜0.05).研究組客觀有效率為57.5％(23/40),對照組為45.3％(24/53),差異無統計學意義(x2＝1.36,P＞0.05).研究組KPS評分上升率(65.0％)高于對照組(39.6％),(x2 ＝5.87,P＜0.05).研究組和對照組無進展生存期分彆為5.38箇月和6.92箇月(x2＝4.04,P＜0.05).結論 人參皂苷Rg3聯閤化療可以降低老年胃癌患者血清VEGF水平,改善患者的一般狀況.
목적 탐토인삼조대Rg3연합XELOX방안대노년위암적치료효과.방법 장학진위노년만기위암(Ⅳ기)적93례환자수궤분위량조:대조조53례(XELOX방안화료);연구조40례(XELOX방안화료+인삼조대Rg3).관찰량조환자적객관유효솔(RR)、원기생활질량(KPS)평분,병검측2조환자혈청혈관내피생장인자(VEGF)수평.결과 연구조、대조조치료전혈청VEGF수평분별위(387.63±159.74)μg/L화(378.56±169.36) ng/L;치료제8주후검측혈청VEGF수평,연구조VEGF수평강지(207.74±115.71)ng/L,대조조VEGF수평강지(246.53±107.63)μg/L.치료후량조조간상비,혈청VEGF수평균유통계학의의(Z＝4.275,P＜0.05).연구조객관유효솔위57.5％(23/40),대조조위45.3％(24/53),차이무통계학의의(x2＝1.36,P＞0.05).연구조KPS평분상승솔(65.0％)고우대조조(39.6％),(x2 ＝5.87,P＜0.05).연구조화대조조무진전생존기분별위5.38개월화6.92개월(x2＝4.04,P＜0.05).결론 인삼조감Rg3연합화료가이강저노년위암환자혈청VEGF수평,개선환자적일반상황.
Objective To evaluate the effects of ginsenoside Rg3 combined with XELDX regimen on advanced carcinoma of stomach.Methods Totally 93 postoperative patients with advanced gastric cancer were randomly divided into two groups:control group(n ＝ 53) who received only XELDX regimen,and study group (n＝ 40) who were treated with ginsenoside Rg3 + XELDX.The objective response rate,KPS score and serum VEGF levels in the two groups were detected.Results (1) Before treatment,treatment group and control group showed that serum VEGF levels were (387.63±159.74) μg/L and (378.56± 169.36) μg/L,respectively (P＜0.05).After 8 weeks of treatment,serum VEGF of the treatment group decreased to (207.74 ± 115.71) μg/L,the level of the control group VEGF decreased to (246.53 ±107.63) μg/L(P＜0.05).(2) The efficacy rate was 57.5％ (23/40) in treatment group and 45.3％(24/53) in the control group (P＞0.05).(3) KPS score increasing rate was higher in treatment group (65.0％) than in control group (39.6％)(x2＝5.87,P＜0.05).Conclusions Ginsenoside Rg3 combined with chemotherapy in advanced gastric cancer patients can reduce serum VEGF levels and improve the quality of life of patients.
